image credit: kjpargeter / Freepik

FDA completes meeting for potential genetic therapy to treat sickle cell disease

November 2, 2023


The potential therapy is the first to emerge from CRISPR’s and Vertex’s strategic partnership, which was expanded in 2021.

Affecting more than 20 million people worldwide, SCD is a group of inherited red blood cell disorders which cause red blood cells to become hard and sticky and appear in a c-shaped form known as ‘sickle’.

The lifelong illness can lead to serious health problems, including strokes, eye problems, infections and episodes of pain.

Read More on PMLiVE